A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects
Keywords: آمیلوئید بتا; Alzheimer's disease; Glutaminyl cyclase; QC inhibitor; Amyloid-beta; Pyroglutamate; pE-Aβ; Cerebrospinal fluid